Naltrexone ER is a Small Molecule owned by Alkermes, and is involved in 30 clinical trials, of which 28 were completed, and 2 are ongoing.

Naltrexone is an opioid antagonist with highest affinity for the mu opioid receptor. It blocks the effects of opioids by competitive binding at opioid receptors and makes the blockade produced potentially surmountable. Thus opioid effects of analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia, and physical dependence are inhibited.

The revenue for Naltrexone ER is expected to reach a total of $4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Naltrexone ER NPV Report.

Naltrexone ER is currently owned by Alkermes.

Naltrexone ER Overview

Naltrexone (Vivitrol) is an opioid antagonist. It is formulated as extended-release injectable powder for suspension for intramuscular route of administration. It is indicated for the treatment of alcohol dependence. It is also indicated for the prevention of relapse to opioid dependence, following opioid detoxification.

Alkermes Overview

Alkermes is a biopharmaceutical company that focuses on the research, development, and commercialization of drugs for the treatment of cancer, neurodegenerative and central nervous system (CNS) diseases. The company’s proprietary products include Aristada and Aristada Initio an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, a once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It also grants licenses under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to pharmaceutical wholesalers, treatment providers, specialty distributors and pharmacies. The company has global operations. Alkermes is headquartered in Dublin, Ireland.

The company reported revenues of (US Dollars) US$1,173.8 million for the fiscal year ended December 2021 (FY2021), an increase of 13% over FY2020. The operating loss of the company was US$32.3 million in FY2021, compared to an operating loss of US$112.4 million in FY2020. The net loss of the company was US$48.2 million in FY2021, compared to a net loss of US$110.9 million in FY2020. The company reported revenues of US$252.4 million for the third quarter ended September 2022, a decrease of 8.6% over the previous quarter.

Quick View – Naltrexone ER

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Naltrexone ER
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.